ImmuCell Corporation (ICCC) has received a recommendation upgrade to “Outperform,” driven by consistent execution across its sales and gross margin profile, alongside emerging strategic optionality linked to its late-stage mastitis treatment, Re-Tain. The company's operational rebound, product mix strength and capacity scaling provide a solid base for continued performance, while developments in product innovation and regulatory progress introduce asymmetric upside potential.Price PerformanceICCC shares hav ...